Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab)

Cat. No. / Size
Price
Availability
Qty
HRF-M789-100ug
$415.00
In Stock - Delivery in 1-2 business days
HRF-M789-1mg
$2,735.00
In Stock - Delivery in 2 weeks
HRF-M789
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to human constant domains.

Antibody Type

Recombinant Monoclonal

Clone

AM789

Isotype

Human IgG1, Kappa

Host Species

Mouse

Reactivity

Virus

Specificity

This product is a specific antibody specifically reacts with HRSV F-Palivizumab.

Application
Application
Recommended Use
ELISA
0.2-2 μg/mL

* Recommended dilutions are for reference only. Optimal working concentrations may vary depending on your consumables, reagents, and assay conditions. We recommend optimizing for your specific system. No warranty is made regarding performance at any specific dilution.

Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.
Antibody Palivizumab, a humanized monoclonal antibody targeting the antigenic site II region of the RSV F protein.